HDL: Quality or quantity?

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 121-123

  Santos Gallego, Carlos G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk; Coronary artery disease; High density lipoprotein; Prognostic factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN; NICOTINIC ACID; ROSUVASTATIN; SPHINGOSINE 1 PHOSPHATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CHOLESTEROL TRANSPORT; CONFORMATIONAL TRANSITION; CORONARY ARTERY DISEASE; CROSS LINKING; DIABETES MELLITUS; GENETIC VARIABILITY; HEART FAILURE; HEART INFARCTION; HUMAN; IN VITRO STUDY; INTERVENTION STUDY; LIPOPROTEIN BLOOD LEVEL; META ANALYSIS; NOTE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION STUDY; BLOOD; CARDIOVASCULAR DISEASE; FEMALE; MALE; PERCUTANEOUS CORONARY INTERVENTION;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; FEMALE; HUMANS; LIPOPROTEINS, HDL; MALE; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84941636048     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.027     Document Type: Note

References (27)

1. Santos-Gallego C.G., Badimon J.J., Rosenson R.S. Beginning to understand high-density lipoproteins. Endocrinol. Metab. Clin. North Am. 2014, 43(4):913-947.
2. Santos-Gallego C.G., Picatoste B., Badimon J.J. Pathophysiology of acute coronary syndrome. Curr. Atheroscler. Rep. 2014, 16(4):401.
3. Izuhara M., Ono K., Shiomi H., Morimoto T., Furukawa Y., Nakagawa Y., Shizuta S., Tada T., Tazaki J., Horie T., Kuwabara Y., Baba O., Nishino T., Kita T., Kimura T. High-density lipoprotein cholesterol levels and cardiovascular outcomes in Japanese patients after percutaneous coronary intervention: a report from the CREDO-Kyoto registry cohort-2. Atherosclerosis 19 May 2015, pii: S0021-9150(15)01311-8, http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.010 [Epub ahead of print].
4. Santos-Gallego C.G., Ibanez B., Badimon J.J. HDL-cholesterol: is it really good? Differences between apoA-I and HDL. Biochem. Pharmacol. 2008, 76(4):443-452.
5. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 1990, 85(4):1234-1241.
6. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991, 353(6341):265-267.
7. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003, 290(17):2292-2300.
8. Voight B.F., Peloso G.M., Orho-Melander M., Frikke-Schmidt R., Barbalic M., Jensen M.K., Hindy G., Holm H., Ding E.L., Johnson T., Schunkert H., Samani N.J., Clarke R., Hopewell J.C., Thompson J.F., Li M., Thorleifsson G., Newton-Cheh C., Musunuru K., Pirruccello J.P., Saleheen D., Chen L., Stewart A., Schillert A., Thorsteinsdottir U., Thorgeirsson G., Anand S., Engert J.C., Morgan T., Spertus J., Stoll M., Berger K., Martinelli N., Girelli D., McKeown P.P., Patterson C.C., Epstein S.E., Devaney J., Burnett M.S., Mooser V., Ripatti S., Surakka I., Nieminen M.S., Sinisalo J., Lokki M.L., Perola M., Havulinna A., de Faire U., Gigante B., Ingelsson E., Zeller T., Wild P., de Bakker P.I., Klungel O.H., Maitland-van der Zee A.H., Peters B.J., de Boer A., Grobbee D.E., Kamphuisen P.W., Deneer V.H., Elbers C.C., Onland-Moret N.C., Hofker M.H., Wijmenga C., Verschuren W.M., Boer J.M., van der Schouw Y.T., Rasheed A., Frossard P., Demissie S., Willer C., Do R, Ordovas J.M., Abecasis G.R., Boehnke M., Mohlke K.L., Daly M.J., Guiducci C., Burtt N.P., Surti A., Gonzalez E., Purcell S., Gabriel S., Marrugat J., Peden J., Erdmann J., Diemert P., Willenborg C., Konig I.R., Fischer M., Hengstenberg C., Ziegler A., Buysschaert I., Lambrechts D., Van de Werf F., Fox K.A., El Mokhtari N.E., Rubin D., Schrezenmeir J., Schreiber S., Schafer A., Danesh J., Blankenberg S., Roberts R., McPherson R., Watkins H., Hall A.S., Overvad K., Rimm E., Boerwinkle E., Tybjaerg-Hansen A., Cupples L.A., Reilly M.P., Melander O., Mannucci P.M., Ardissino D., Siscovick D., Elosua R., Stefansson K., O'Donnell C.J., Salomaa V., Rader D.J., Peltonen L., Schwartz S.M., Altshuler D., Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012, 380(9841):572-580.
9. Ridker P.M., Genest J., Boekholdt S.M., Libby P., Gotto A.M., Nordestgaard B.G., Mora S., MacFadyen J.G., Glynn R.J., Kastelein J.J. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010, 376(9738):333-339.
10. Ray K., Wainwright N.W., Visser L., Witteman J., Breteler M., Ambegaonkar B., Hofman A., Stricker B., Wareham N., Khaw K.T., Sandhu M. Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy. Heart 2012, 98(10):780-785.
11. Briel M., Ferreira-Gonzalez I., You J.J., Karanicolas P.J., Akl E.A., Wu P., Blechacz B., Bassler D., Wei X., Sharman A., Whitt I., Alves da Silva S., Khalid Z., Nordmann A.J., Zhou Q., Walter S.D., Vale N., Bhatnagar N., O'Regan C., Mills E.J., Bucher H.C., Montori V.M., Guyatt G.H. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009, 338. b92.
12. Boden W.E., Probstfield J.L., Anderson T., Chaitman B.R., Desvignes-Nickens P., Koprowicz K., McBride R., Teo K., Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 2011, 365(24):2255-2267.
13. Landray M.J., Haynes R., Hopewell J.C., Parish S., Aung T., Tomson J., Wallendszus K., Craig M., Jiang L., Collins R., Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 2014, 371(3):203-212.
14. Santos-Gallego C.G., Giannarelli C., Badimon J.J. Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. Curr. Atheroscler. Rep. 2011, 13(3):266-276.
15. Khera A.V., Cuchel M., de la Llera-Moya M., Rodrigues A., Burke M.F., Jafri K., French B.C., Phillips J.A., Mucksavage M.L., Wilensky R.L., Mohler E.R., Rothblat G.H., Rader D.J. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 2011, 364(2):127-135.
16. Rohatgi A., Khera A., Berry J.D., Givens E.G., Ayers C.R., Wedin K.E., Neeland I.J., Yuhanna I.S., Rader D.R., de Lemos J.A., Shaul P.W. HDL cholesterol efflux capacity and incident cardiovascular events. N. Engl. J. Med. 2014, 371(25):2383-2393.
17. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001, 103(18):2283-2288.
18. Santos-Gallego C.G., Rosenson R.S. Role of HDL in those with diabetes. Curr. Cardiol. Rep. 2014, 16(8):512.
19. Huang Y., Didonato J.A., Levison B.S., Schmitt D., Li L., Wu Y., Buffa J., Kim T., Gerstenecker G.S., Gu X., Kadiyala C.S., Wang Z., Culley M.K., Hazen J.E., Didonato A.J., Fu X., Berisha S.Z., Peng D., Nguyen T.T., Liang S., Chuang C.C., Cho L., Plow E.F., Fox P.L., Gogonea V., Tang W.H., Parks J.S., Fisher E.A., Smith J.D., Hazen S.L. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat. Med. Feb 2014, 20(2):193-203. [Epub 26 Jan 2014]. 10.1038/nm.3459.
20. Sattler K., Gräler M., Keul P., Weske S., Reimann C.M., Jindrová H., Kleinbongard P., Sabbadini R., Bröcker-Preuss M., Erbel R., Heusch G., Levkau B. Signaling and functional defects of high-density lipoproteins (HDL) in coronary artery disease (CAD) are caused by low sphingosine-1-phosphate (S1P) content and can be efficiently corrected by HDL loading with S1P. J. Am. Coll. Cardiol. 2015, 66(13). In press.
21. Badimon J., Santos-Gallego C.G. HDL dysfunction: is the answer in the sphinx's riddle?. J. Am. Coll. Cardiol. 2015, 66(13). In press.
22. Mackey R.H., Greenland P., Goff D.C., Lloyd-Jones D., Sibley C.T., Mora S. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 2012, 60(6):508-516.
23. Otvos J.D., Collins D., Freedman D.S., Shalaurova I., Schaefer E.J., McNamara J.R., Bloomfield H.E., Robins S.J. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans affairs high-density lipoprotein intervention trial. Circulation 2006, 113(12):1556-1563.
24. Vergeer M., Boekholdt S.M., Sandhu M.S., Ricketts S.L., Wareham N.J., Brown M.J., de Faire U., Leander K., Gigante B., Kavousi M., Hofman A., Uitterlinden A.G., van Duijn C.M., Witteman J.C., Jukema J.W., Schadt E.E., van der Schoot E., Kastelein J.J., Khaw K.T., Dullaart R.P., van Tol A., Trip M.D., Dallinga-Thie G.M. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122(5):470-477.
25. Mora S., Glynn R.J., Ridker P.M. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 2013, 128(11):1189-1197.
26. Khera A.V., Patel P.J., Reilly M.P., Rader D.J. The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J. Am. Coll. Cardiol. 2013, 62(20):1909-1910.
27. Airan-Javia S.L., Wolf R.L., Wolfe M.L., Tadesse M., Mohler E., Reilly M.P. Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. Am. Heart J. 2009, 157(4):687. e681-688.